← Leaderboards
Yuntao Wu
George Mason University
$7,698,893
Attributed
$8,205,585
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,205,585 · 8
By mechanism
R01$6,463,984 · 3
R56$760,038 · 1
R21$698,178 · 2
R03$283,385 · 2
Top collaborators
- Mohsin Saleet Jafri1 shared
- Dmitri Konstantinovich Klimov1 shared
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralCellsInfectionHiv InfectionsHiv-1BaseMediatingCd4 Positive T LymphocytesT-LymphocyteVirusMigrationLaboratoriesParticleVirionMonitorAmino AcidsProteinsLeadAcquired Immunodeficiency SyndromeGlycoproteinsMutagenesisSitePathway InteractionsTissues
Grant awards (23)
Molecular Modeling of the DR domain of an HIV restriction factor PSGL-1$760,038
R56 · FY2024 · AI · contact PI
Mechanisms of PSGL-1 restriction of HIV virion infectivity$385,591
R01 · FY2024 · AI · contact PI
Mechanisms of PSGL-1 restriction of HIV virion infectivity$385,928
R01 · FY2023 · AI · contact PI
Mechanisms of PSGL-1 restriction of HIV virion infectivity$386,241
R01 · FY2022 · AI · contact PI
Mechanisms of PSGL-1 restriction of HIV virion infectivity$386,530
R01 · FY2021 · AI · contact PI
Mechanisms of PSGL-1 restriction of HIV virion infectivity$386,797
R01 · FY2020 · AI · contact PI
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs$652,436
R01 · FY2018 · MH · contact PI
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs$652,436
R01 · FY2017 · MH · contact PI
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs$672,006
R01 · FY2016 · MH · contact PI
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs$672,006
R01 · FY2015 · MH · contact PI
Development of a novel HIV-1 nuclear localization assay$71,164
R03 · FY2015 · AI · contact PI
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs$653,018
R01 · FY2014 · MH · contact PI
Development of a novel HIV-1 nuclear localization assay$70,452
R03 · FY2014 · AI · contact PI
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells$305,234
R01 · FY2012 · AI · contact PI
Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin$70,745
R03 · FY2012 · AI · contact PI
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells$305,365
R01 · FY2011 · AI · contact PI
Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin$71,024
R03 · FY2011 · AI · contact PI
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells$308,577
R01 · FY2010 · AI · contact PI
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells$311,819
R01 · FY2009 · AI · contact PI
Determine the Transcriptional Activity of Non-integrated HIV-1 DNA$203,758
R21 · FY2008 · AI · contact PI
Determine the Transcriptional Activity of Non-integrated HIV-1 DNA$136,552
R21 · FY2007 · AI · contact PI
Targeting Brain Macrophages by a novel lentiviral vector$226,076
R21 · FY2006 · NS · contact PI
Targeting Brain Macrophages by a novel lentiviral vector$131,792
R21 · FY2005 · NS